June 5th – Alberleen Family Office Solutions (AFOS) proudly hosted a Lunch n’ Learn session for clinical stage cell therapy company TC Biopharm. TCB is based in Scotland and was founded by cell therapy veteran CEO Michael Leek. It is developing allogeneic Gamma Delta T-Cell therapies for patients in a number of oncology indications and has expanded that unique, proprietary platform to begin developing dual activated CAR-T therapies. CEO Leek and his team are dedicated to developing low cost, broadly accessible cell therapy treatments for cancer and have made great strides to become the leader in the allogeneic cell therapy sector.
TC Biopharm has announced partnerships with drug development behemoths such as bluebird bio (Nasdaq: BLUE) and NIPRO Japan, where they are exploring applications for Gamma Delta T-Cell therapy in indications such as Acute Myeloid Leukemia (AML), Melanoma, Non-Small Cell Lung Cancer (NSCLC) and a number of pediatric indications. CEO Leek discussed the Company’s completed clinical Phase 1/2 data in Melanoma, their Phase 1/2 trial structure and focus in AML and the developing CAR-T dynamic that could revolutionize the treatment paradigm of cancer, bringing off the shelf CAR-T treatments at significantly lower costs to patients.
To date, roughly $36 Million in capital has flowed into TC Biopharm, $24 Million in non-dilutive milestone payments from their partners and grants, and an additional $12 Million has been raised from investors such as Scottish Investment Bank.
We were excited to hear how Mike and his team have built such a potentially impactful therapeutic technology suite in such a short time since their founding roughly 6 years ago, and we thank all our attendees for joining us.
For more information please contact, Bryan Kobel at Bryan@alberleen.com (212) 993-7422
Alberleen Family Office Innovation Summit in Salt Lake City, UT